

§ 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

***Amendments***

***In the Claims:***

Please cancel claims 4 and 8-12.

Please substitute pending claims 1-3 and 5-7 with the following claims 1-3, and 5-7:

1. (Once Amended) A method of treatment or prevention of metastasis of cancer cells consisting essentially of administering to a patient in need of treatment an effective amount of an angiotensin.

2. (Once Amended) The method as claimed in claim 1, wherein said cancer cells are derived from at least one of the group consisting of breast, skin, large bowel, prostate, lung, bone, cervix, stomach and rectum.

3. (Once Amended) The method as claimed in claim 1, wherein said angiotensin is angiotensin-II.

5. (Twice Amended) The method as claimed in claim 1, wherein said administering is oral, rectal, nasal, topical, vaginal, or parenteral.

6. (Twice Amended) The method as claimed in claim 1, wherein said administering is subcutaneous, intramuscular, intravenous, or intradermal.

7. (Once Amended) A method of inducing the expression of  $\beta_1$  integrin molecules in cancer cells consisting essentially of administering to a patient an effective amount of an angiotensin.

Please add the following new claims:

14. (New) The method as claimed in claim 1, wherein said administering further comprises an excipient or carrier.

15. (New) The method as claimed in claim 7, wherein said administering further comprises an excipient or carrier.

16. (New) A method of treatment or prevention of metastasis of cancer cells comprising administering to a patient in need of treatment an effective amount of an angiotensin, wherein said cancer cells are derived from at least one of the group consisting of skin, prostate, lung, bone and cervix.

17. (New) The method as claimed in claim 16, wherein said administering further comprises an excipient or carrier.

18. (New) The method as claimed in claim 16, wherein said angiotensin is angiotensin-II.

19. (New) The method as claimed in claim 16, wherein said administering is oral, rectal, nasal, topical, vaginal, or parenteral.

20. (New) The method as claimed in claim 16, wherein said administering is subcutaneous, intramuscular, intravenous, or intradermal.

21. (New) A method of inducing the expression of  $\beta_1$  integrin molecules in cancer cells comprising administering to a patient an effective amount of an angiotensin, wherein said cancer cells are derived from at least one of the group consisting of skin, prostate, lung, bone and cervix.

22. (New) The method as claimed in claim 21, wherein said administering further comprises an excipient or carrier.

23. (New) The method as claimed in claim 21, wherein said angiotensin is angiotensin-II.

24. (New) The method as claimed in claim 21, wherein said administering is oral, rectal, nasal, topical, vaginal, or parenteral.

25. (New) The method as claimed in claim 21, wherein said administering is subcutaneous, intramuscular, intravenous, or intradermal.